Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CVRX
Upturn stock ratingUpturn stock rating

CVRx Inc (CVRX)

Upturn stock ratingUpturn stock rating
$5.88
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CVRX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $11

1 Year Target Price $11

Analysts Price Target For last 52 week
$11Target price
Low$4.3
Current$5.88
high$18.55

Analysis of Past Performance

Type Stock
Historic Profit 47.1%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 151.74M USD
Price to earnings Ratio -
1Y Target Price 11
Price to earnings Ratio -
1Y Target Price 11
Volume (30-day avg) 7
Beta 1.25
52 Weeks Range 4.30 - 18.55
Updated Date 06/30/2025
52 Weeks Range 4.30 - 18.55
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.14

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -97.49%
Operating Margin (TTM) -108.82%

Management Effectiveness

Return on Assets (TTM) -26.88%
Return on Equity (TTM) -76.01%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 100019978
Price to Sales(TTM) 2.87
Enterprise Value 100019978
Price to Sales(TTM) 2.87
Enterprise Value to Revenue 1.89
Enterprise Value to EBITDA -1.31
Shares Outstanding 26072600
Shares Floating 17884239
Shares Outstanding 26072600
Shares Floating 17884239
Percent Insiders 4.26
Percent Institutions 73.63

Analyst Ratings

Rating 3
Target Price 11
Buy 1
Strong Buy 5
Buy 1
Strong Buy 5
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

CVRx Inc

stock logo

Company Overview

overview logo History and Background

CVRx, Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota. The company is focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. CVRx went public in 2021. The company initially focused on treating hypertension but has expanded its focus to heart failure.

business area logo Core Business Areas

  • Barostim Therapy for Heart Failure: CVRx's primary focus is its Barostim system for treating heart failure with reduced ejection fraction. This device stimulates baroreceptors in the carotid artery to modulate autonomic nervous system activity, improving heart function and reducing symptoms.

leadership logo Leadership and Structure

The leadership team includes Nadim Yared (President and CEO), and a board of directors.

Top Products and Market Share

overview logo Key Offerings

  • Barostim NEO System: The Barostim NEO system is CVRx's lead product. It is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery to treat heart failure. Market share data is unavailable. Competitors include companies offering alternative heart failure treatments, such as drug therapies from companies like Novartis (NVS) and Abbott (ABT) with their CardioMEMS HF system.

Market Dynamics

industry overview logo Industry Overview

The cardiovascular device market is a large and growing market, driven by the increasing prevalence of heart failure, hypertension, and other cardiovascular diseases. The industry is characterized by innovation, with companies constantly developing new and improved devices to treat these conditions.

Positioning

CVRx is positioned as a leader in neuromodulation therapy for heart failure. Its Barostim system offers a unique approach to treating heart failure by modulating the autonomic nervous system.

Total Addressable Market (TAM)

The TAM for heart failure therapies is significant, estimated to be in the billions of dollars. CVRx is positioned to capture a portion of this market with its Barostim system.

Upturn SWOT Analysis

Strengths

  • Innovative neuromodulation technology
  • FDA-approved device for heart failure
  • Strong clinical evidence supporting Barostim's efficacy

Weaknesses

  • Limited commercial presence
  • High cost of therapy
  • Dependence on a single product

Opportunities

  • Expanding indications for Barostim
  • Increasing awareness of neuromodulation therapy
  • Partnerships with larger medical device companies

Threats

  • Competition from established heart failure therapies
  • Reimbursement challenges
  • Potential for adverse events associated with Barostim

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • ABT
  • BSX

Competitive Landscape

CVRx's Barostim system offers a unique neuromodulation approach, but it faces competition from established drug therapies and devices offered by larger companies.

Growth Trajectory and Initiatives

Historical Growth: Historical revenue growth has been dependent on adoption rates of the Barostim system.

Future Projections: Analyst projections suggest continued revenue growth driven by increased adoption of Barostim and potential expansion into new markets.

Recent Initiatives: Recent initiatives include expanding the sales force and conducting clinical trials to support broader adoption of Barostim.

Summary

CVRx is a developing company with an innovative product for heart failure. While its Barostim system offers a unique approach and has shown promising results, the company faces challenges related to commercialization, reimbursement, and competition. Its future success depends on its ability to expand market adoption and demonstrate long-term clinical benefits. CVRX needs to monitor competitor offerings and reimbursement changes for its product to remain successful.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports (where available)

Disclaimers:

This analysis is based on publicly available information and limited financial data. It is not financial advice. Market share data is approximate and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CVRx Inc

Exchange NASDAQ
Headquaters Minneapolis, MN, United States
IPO Launch date 2021-06-30
President, CEO & Director Mr. Kevin Hykes
Sector Healthcare
Industry Medical Devices
Full time employees 206
Full time employees 206

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.